Brind.

Aptar and Australian Research Council launch dry powder biologic research

1 report, 1 independent Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Aptar Pharma announced a three-year research collaboration with Macquarie University, supported by the Australian Research Council. The project aims to investigate formulation approaches for the pulmonary delivery of biologic medicines. Researchers will evaluate how formulation variables influence aerosol performance when using Aptar's Orbital dry powder inhaler platform.

From finanznachrichten.de

Why it matters

Some supportBrind's analysis of the reports

The initiative addresses challenges faced by developers in delivering large doses of complex biologic molecules while maintaining formulation integrity. As interest in inhaled biologic therapies grows, this research aims to generate new insights into the interplay between formulation design and device performance.

From finanznachrichten.de

Who's involved

  • AptarGlobal drug delivery company collaborating on a three-year research initiative.
  • Australian Research CouncilAustralian government funding body supporting the research project.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped